Nakamichi S - Search Results

1

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer.

Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda K, Kato Y, Nakamichi S, Takeuchi S, Matsumoto M, Miyanaga A, Kunugi S, Honda K, Adachi J, Seike M. Tozuka T, et al. Among authors: nakamichi s. JTO Clin Res Rep. 2024 Mar 21;5(4):100668. doi: 10.1016/j.jtocrr.2024.100668. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38646155 Free PMC article.

2

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.

Takahashi A, Seike M, Chiba M, Takahashi S, Nakamichi S, Matsumoto M, Takeuchi S, Minegishi Y, Noro R, Kunugi S, Kubota K, Gemma A. Takahashi A, et al. Among authors: nakamichi s. Sci Rep. 2018 Oct 5;8(1):14896. doi: 10.1038/s41598-018-33190-8. Sci Rep. 2018. PMID: 30291293 Free PMC article.

3

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer.

Tozuka T, Noro R, Miyanaga A, Nakamichi S, Takeuchi S, Matsumoto M, Kubota K, Kasahara K, Seike M. Tozuka T, et al. Among authors: nakamichi s. Cancer Med. 2023 Sep;12(17):17731-17739. doi: 10.1002/cam4.6393. Epub 2023 Sep 11. Cancer Med. 2023. PMID: 37691552 Free PMC article.

4

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.

Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, Kubota K, Gemma A. Sugano T, et al. Among authors: nakamichi s. Mol Cancer Ther. 2015 Nov;14(11):2433-40. doi: 10.1158/1535-7163.MCT-15-0050. Epub 2015 Sep 8. Mol Cancer Ther. 2015. PMID: 26351321

5

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.

Nakamichi S, Seike M, Miyanaga A, Chiba M, Zou F, Takahashi A, Ishikawa A, Kunugi S, Noro R, Kubota K, Gemma A. Nakamichi S, et al. Oncotarget. 2018 Jun 5;9(43):27242-27255. doi: 10.18632/oncotarget.25531. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930762 Free PMC article.

6

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.

Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, Nakamichi S, Sugano T, Hirao M, Matsuda K, Hamada M, Gemma A. Takahashi S, et al. Among authors: nakamichi s. Int J Mol Sci. 2021 Apr 13;22(8):4005. doi: 10.3390/ijms22084005. Int J Mol Sci. 2021. PMID: 33924522 Free PMC article.

7

A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.

Takano N, Seike M, Sugano T, Matsuda K, Hisakane K, Yoshikawa A, Nakamichi S, Noro R, Gemma A. Takano N, et al. Among authors: nakamichi s. Anticancer Res. 2022 Feb;42(2):709-722. doi: 10.21873/anticanres.15529. Anticancer Res. 2022. PMID: 35093869

8

Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer.

Hisakane K, Seike M, Sugano T, Matsuda K, Kashiwada T, Nakamichi S, Matsumoto M, Miyanaga A, Noro R, Kubota K, Gemma A. Hisakane K, et al. Among authors: nakamichi s. Gene. 2023 Mar 20;857:147177. doi: 10.1016/j.gene.2023.147177. Epub 2023 Jan 7. Gene. 2023. PMID: 36623674

9

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report.

Misawa K, Nakamichi S, Iida H, Nagano A, Mikami E, Tozuka T, Matsumoto M, Miyanaga A, Noro R, Kubota K, Yamaguchi H, Seike M. Misawa K, et al. Among authors: nakamichi s. Onco Targets Ther. 2023 Jan 24;16:65-69. doi: 10.2147/OTT.S398375. eCollection 2023. Onco Targets Ther. 2023. PMID: 36718244 Free PMC article.

10

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.

Iso H, Miyanaga A, Kadoma N, Shinbu K, Tozuka T, Murata A, Nishima S, Sato Y, Nakamichi S, Matsumoto M, Noro R, Terasaki Y, Kubota K, Seike M. Iso H, et al. Among authors: nakamichi s. Onco Targets Ther. 2023 Jun 23;16:465-470. doi: 10.2147/OTT.S404035. eCollection 2023. Onco Targets Ther. 2023. PMID: 37384219 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page